PAR DRUGS AND CHEMICALS
|
PAR DRUGS AND CHEMICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.86 | 11.79 | 9.21 | 7.49 | 18.87 |
| CEPS(Rs) | 13.82 | 14.58 | 11.84 | 10.15 | 11.73 |
| DPS(Rs) | - | - | - | 1.25 | - |
| Book NAV/Share(Rs) | 80.44 | 69.59 | 57.90 | 48.66 | 84.87 |
| Tax Rate(%) | 25.47 | 25.70 | 24.84 | 27.47 | 21.15 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.20 | 21.27 | 16.81 | 19.16 | 23.18 |
| EBIT Margin(%) | 15.88 | 18.29 | 14.04 | 15.51 | 22.25 |
| Pre Tax Margin(%) | 15.81 | 18.20 | 13.92 | 14.97 | 21.32 |
| PAT Margin (%) | 11.78 | 13.52 | 10.46 | 10.86 | 16.81 |
| Cash Profit Margin (%) | 15.00 | 16.72 | 13.45 | 14.73 | 20.89 |
| Performance Ratios | |||||
| ROA(%) | 12.09 | 15.23 | 13.53 | 11.88 | 17.01 |
| ROE(%) | 14.47 | 18.49 | 17.29 | 16.44 | 25.02 |
| ROCE(%) | 19.51 | 25.02 | 23.20 | 21.85 | 28.68 |
| Asset Turnover(x) | 1.03 | 1.13 | 1.29 | 1.09 | 1.01 |
| Sales/Fixed Asset(x) | 1.52 | 1.52 | 1.70 | 1.51 | 1.26 |
| Working Capital/Sales(x) | 2.96 | 2.27 | 3.06 | 2.96 | 2.74 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.66 | 0.66 | 0.59 | 0.66 | 0.80 |
| Receivable days | 48.97 | 52.21 | 59.70 | 66.50 | 65.58 |
| Inventory Days | 16.55 | 16.26 | 17.00 | 16.58 | 15.63 |
| Payable days | 77.76 | 72.63 | 84.87 | 110.04 | 107.79 |
| Valuation Parameters | |||||
| PER(x) | 7.82 | 18.28 | 15.20 | 21.34 | 3.28 |
| PCE(x) | 6.15 | 14.78 | 11.83 | 15.73 | 5.28 |
| Price/Book(x) | 1.06 | 3.10 | 2.42 | 3.28 | 1.46 |
| Yield(%) | - | - | - | 0.78 | - |
| EV/Net Sales(x) | 0.76 | 2.39 | 1.57 | 2.40 | 1.04 |
| EV/Core EBITDA(x) | 3.55 | 9.91 | 8.13 | 10.97 | 3.91 |
| EV/EBIT(x) | 4.27 | 11.64 | 9.86 | 13.71 | 4.12 |
| EV/CE(x) | 0.78 | 2.67 | 2.11 | 2.29 | 0.83 |
| M Cap / Sales | 1.03 | 2.77 | 1.80 | 2.62 | 1.25 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.58 | -0.11 | 27.54 | 23.58 | 8.78 |
| Core EBITDA Growth(%) | -6.11 | 25.02 | 12.21 | 1.46 | 69.70 |
| EBIT Growth(%) | -8.25 | 29.00 | 15.62 | -14.39 | 126.48 |
| PAT Growth(%) | -7.88 | 27.94 | 23.02 | -20.65 | 143.68 |
| EPS Growth(%) | -7.88 | 27.94 | 23.02 | -60.33 | 143.68 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | 0.16 |
| Current Ratio(x) | 3.31 | 4.79 | 3.53 | 2.93 | 2.58 |
| Quick Ratio(x) | 2.94 | 4.46 | 3.15 | 2.61 | 2.39 |
| Interest Cover(x) | 219.31 | 183.23 | 114.21 | 28.97 | 23.93 |
| Total Debt/Mcap(x) | - | - | - | - | 0.11 |
Compare Financial Ratios of peers of PAR DRUGS AND CHEMICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| PAR DRUGS AND CHEMICALS | ₹140.7 Cr | -5.8% | -18.8% | 8.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹419,620.0 Cr | -0.2% | -5.1% | 8.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,714.0 Cr | -3.8% | -3.2% | 51.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹174,741.0 Cr | -1.7% | -7.7% | 29.9% | Stock Analytics | |
| CIPLA | ₹106,061.0 Cr | 0.6% | -3.8% | -11% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,339.0 Cr | 2.9% | 4.6% | 0.4% | Stock Analytics | |
PAR DRUGS AND CHEMICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PAR DRUGS AND CHEMICALS | -5.8% |
-18.8% |
8.1% |
| SENSEX | 0.2% |
-2.8% |
-11.2% |
You may also like the below Video Courses
